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Voltage-gated ion channelsThe plant alkaloid ibogaine has promising anti-addictive properties. Albeit not licenced as a therapeutic drug,
and despite hints that ibogaine may perturb the heart rhythm, this alkaloid is used to treat drug addicts. We
have recently reported that ibogaine inhibits human ERG (hERG) potassium channels at concentrations
similar to the drugs afﬁnity for several of its known brain targets. Thereby the drug may disturb the heart's
electrophysiology.
Here, to assess the drug's cardiac ion channel proﬁle in more detail, we studied the effects of ibogaine and its
congener 18-Methoxycoronaridine (18-MC) on various cardiac voltage-gated ion channels. We conﬁrmed
that heterologously expressed hERG currents are reduced by ibogaine in low micromolar concentrations.
Moreover, at higher concentrations, the drug also reduced human Nav1.5 sodium and Cav1.2 calcium
currents. Ion currents were as well reduced by 18-MC, yet with diminished potency. Unexpectedly, although
blocking hERG channels, ibogaine did not prolong the action potential (AP) in guinea pig cardiomyocytes at
low micromolar concentrations. Higher concentrations (≥10 μM) even shortened the AP. These ﬁndings can
be explained by the drug's calcium channel inhibition, which counteracts the AP-prolonging effect generated
by hERG blockade. Implementation of ibogaine's inhibitory effects on human ion channels in a computer
model of a ventricular cardiomyocyte, on the other hand, suggested that ibogaine does prolong the AP in
the human heart. We conclude that therapeutic concentrations of ibogaine have the propensity to prolong
the QT interval of the electrocardiogram in humans. In some cases this may lead to cardiac arrhythmias.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
Ibogaine, an indole alkaloid derived from the root bark of the
African shrub Tabernanthe iboga, has received much attention because
of its promising “anti-addictive actions” (for reviews see Alper, 2001;
Maciulaitis et al., 2008). Thus, in animals, ibogaine attenuates opioid
withdrawal signs and reduces the self-administration of a variety of
drugs including opioids, cocaine, nicotine, and alcohol (Alper, 2001;
Glick andMaisonneuve, 1998). In addition, ibogaine hampers responses
that are associated with addiction, such as dopamine release in the
nucleus accumbens of the brain (Benwell et al., 1996; Maisonneuve et
al., 1991). Ibogaine's precise mechanisms of action remain unclear,Gene; 18-MC, 18-Methoxy-
harmacology, Department of
f Vienna, Schwarzspanierstrasse
(K. Hilber).
nc. Open access under CC BY license.but its effects may emerge from complex interactions with multiple
neurotransmitter systems. Accordingly, ibogaine interactswith numerous
different cellular and molecular targets, e.g. neurotransmitter
transporters, opioid receptors, sigma receptors, glutamate receptors,
and nicotinic receptors (Alper, 2001; Glick and Maisonneuve, 1998;
Glick et al., 2000; Maciulaitis et al., 2008).
Ibogaine has a long history of use as a medicinal and ceremonial
agent in West Central Africa. Besides its own psychoactive properties,
anecdotal evidence suggests that ibogaine also acts as an anti-
addictive in humans. Thus, intake of this alkaloid alleviates drug
craving and impedes relapse of drug use (Alper, 2001; Maciulaitis et
al., 2008; Mash et al., 1998). In spite of its status as a banned
substance in the U.S. and some European countries, ibogaine is legal
in most of the world, and, although not licenced as a therapeutic
drug, is currently used as an anti-addiction drug in alternativemedicine
(Alper et al., 2008; Vastag, 2005).
Because ibogaine has a complex pharmacology and is known to
interact with numerous different targets (see above), its potential to
generate adverse effects is signiﬁcant. Besides the expected neurotoxic
actions (e.g. (Alper, 2001; Maciulaitis et al., 2008; Molinari et al.,
1996; O'Hearn and Molliver, 1993; Xu et al., 2000)), ibogaine also
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decreased the heart rate without altering blood pressure (Binienda et
al., 1998; Glick et al., 2000). This ﬁnding is consistent with anecdotal
reports in humans that ibogaine slows the heart rate (Alper, 2001;
Glick et al., 2000; Maciulaitis et al., 2008). Alarming are several cases
of sudden deaths after ibogaine use with unclear cause (Alper et al.,
2012; Donnelly, 2011), which have been hypothesised to be related to
cardiac arrhythmias (Alper et al., 2012; Hoelen et al., 2009; Maas
and Strubelt, 2006). Due to concomitant medications used and
comorbidities present in the patients described in these cases, however,
it is unclear whether ibogaine alone or in combination with other
factors may contribute to the clinical adverse ﬁndings. Recently several
cases of ibogaine-associated QT interval prolongation and arrhythmias
were reported (Hoelen et al., 2009; Paling et al., 2012; Pleskovic et al.,
2012). In a ﬁrst attempt to elucidate the mechanism(s) by which
ibogaine may account for the described clinical observations, we
recently (Koenig et al., 2012) tested the drug's propensity to inhibit
human ERG (hERG, IKr) potassium currents. hERG channels are crucial
for the repolarisation phase of the cardiac action potential (AP), and
hERG channel blockade by drugs is considered the most common
reason for drug-induced QT interval prolongation, which can be
associated with an increased cardiac arrhythmia risk (Redfern et al.,
2003; Sanguinetti and Tristani-Firouzi, 2006). Indeed, we found that
ibogaine reduces hERG currents (IC50, 4 μM) at concentrations similar
to the drug's afﬁnities for several of its known targets in the brain
(Koenig et al., 2012). Thus our ﬁnding matches with the described
reports of QT interval prolongation after ibogaine intake (Hoelen et al.,
2009; Paling et al., 2012; Pleskovic et al., 2012).
Here, to study in more detail the possibly harmful impacts of
ibogaine on the heart's electrophysiology, we explored the drug's
effects on the function of various cardiac voltage-gated ion channels.
Therefore, human ion channels that contribute signiﬁcantly to
the action potential (hERG potassium channels, hNav1.5 sodium
channels, and hCav1.2 calcium channels) were heterologously
expressed in TSA-201 cells. In addition, ibogaine's effects on
the cardiac AP were assessed in experiments on ventricular
cardiomyocytes derived from adult guinea pig hearts, and in simula-
tions using a computer model of a human ventricular cardiomyocyte.
In an effort to estimate margins of safety for this drug between the
ion channel potencies in vitro and human clinical exposure, we
determined human plasma protein binding of the drug. Moreover,
we also tested its synthetic congener 18-Methoxycoronaridine
(18-MC), which exhibits anti-addictive effects but is believed to be
less toxic (Glick et al., 1996, 2000, 2001, 2011).
Materials and methods
The study complies with the rules of the University Animal
Welfare Committee. All of the procedures were conducted in accordance
with the European Community Council Directive for Care and Use of
Laboratory Animals.
Culture and transfection of TSA-201 cells
TSA-201 cells (American Type Culture Collection (ATCC, Manassas,
VA, USA)) were propagated in a Dulbecco's modiﬁed Eagle's medium
(DMEM, Invitrogen, Vienna, Austria) containing 10% foetal bovine
serum (FBS), 50 U/ml penicillin, and 50 U/ml streptomycin, and
were incubated at 37 °C in a humidiﬁed incubator with 5% CO2.
Cells were transfected with pCEP4-plasmid (0.7 μg per 3.5 cm dish)
containing the coding sequence for the human cardiac hERG potassi-
um channel, or pGEM3-plasmid (1–2 μg per 3.5 cm dish) containing
the coding sequence for the human cardiac hNav1.5 sodium channel.
For hCav1.2 calcium current expression, an equimolar ratio of cDNA
(1 μg per 3.5 cm dish) encoding for hCav1.2 α1 subunit (77-pcDNA3)
together with auxiliary rCavβ3 and rCavα2δ1 subunits was used.77-pcDNA3 (Soldatov et al., 2000) was used in this work with the
permission of Dr. Nikolai M. Soldatov (Humgenex, Inc., Maryland,
USA). Cotransfection with pEGFP-C1-plasmid (0.02 μg) encoding
green ﬂuorescent protein (GFP) allowed the identiﬁcation of successfully
transfected cells. For transfection of hERG, hNav1.5 and hCav1.2,
ExGen 500 (Fermentas, St. Leon-Rot, Germany) and FuGENE (Promega,
Mannheim, Germany) were used according to the manufacturer's
protocol.
Isolation of adult guinea pig ventricular cardiomyocytes
Ventricular cardiomyocytes from adult female Dunkin-Hartley
guinea pigs (200–400 g) were isolated using a Langendorff setup
following procedures previously described (Koenig et al., 2011).
Drug sources and preparation of stock solutions
Ibogaine hydrochloride originated from Sacrament of Transition
(Maribor, Slovenia). 18-Methoxycoronaridine (18-MC) racemate
was purchased from Obiter Research (Champaign, IL, USA). Both
drugs were dissolved in 0.1% HCl, and stock solutions with various
concentrations in the range of 1 μM to 30 mM (upper solubility
limit) were prepared. These stocks were stored at −20 °C. On the
day of the experiment, stock aliquots were freshly diluted 1:100
with the respective bath solutions to obtain ﬁnal drug concentrations
(range between 0.01 and 300 μM). The drug-free control bath solutions
contained the same amount of HCl than the experimental solutions.
Because of limitations in drug solubility in our bath solutions, we
refrained from using higher drug end concentrations than 300 μM.
E-4031 and isradipine were purchased from Sigma-Aldrich (Vienna,
Austria).
Electrophysiological studies using the whole cell patch clamp technique
A detailed description of the electrophysiological recordings is given
in our earlier work (Mille et al., 2009; Zebedin et al., 2008). Ionic
currents were recorded from TSA-201 cells 24–48 h after transfection,
and from adult cardiomyocytes up to 12 h after preparation at room
temperature (22 ± 1.5 °C), using an Axoclamp 200B patch clamp
ampliﬁer (Axon Instruments, Union City, CA). Pipettes were formed
from aluminosilicate glass (A120-77-10; Science Products, Hofheim,
Germany) with a P-97 horizontal puller (Sutter Instruments, Novato,
CA), and had resistances between 0.8 and 2 MΩ when ﬁlled with
the respective pipette solutions (see below). Data acquisition was
performed with pClamp 6.0 software (Axon Instruments) through a
12-bit A-D/D-A interface (Digidata 1200; Axon Instruments). Data
were low-pass ﬁltered with 1–10 kHz (−3 dB) and digitised at
10–100 kHz. Data analysis was performed using Clampﬁt 10.2 (Axon
Instruments) and GraphPad Prism 5.01 (San Diego, USA) software.
Rapid solution changes were performed by a DAD-8-VC superfusion
system (ALA Scientiﬁc Instruments, Westbury, NY, USA).
hERG potassium currents. The pipette solution contained 130 mM
KCl, 5 mM MgCl2, 5 mM K2-ATP, 5 mM EGTA, 10 mM HEPES
(pH = 7.2, adjusted with KOH). Recordings were made in a bath
solution that consisted of 137 mM NaCl, 4 mM KCl, 1.8 mM CaCl2,
1 mM MgCl2, 10 mM glucose, 10 mM HEPES, pH = 7.4 adjusted
with NaOH.
Sodium currents. The pipette solution contained 105 mM CsF,
10 mM NaCl, 10 mM EGTA, 10 mM HEPES, pH = 7.3 adjusted with
CsOH. Recordings of hNav1.5 sodium channels expressed in TSA-201
cells were made in a bath solution that consisted of 140 mM NaCl,
2.5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, pH = 7.4
adjusted with NaOH.
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2 mM MgCl2, 10 mM HEPES, 0.1 mM Cs-EGTA, 2 mM Mg-ATP,
pH = 7.4 adjusted with CsOH. The bath solution contained 10 mM
BaCl2, 145 mM TEA-Cl, 10 mM HEPES, pH = 7.4 adjusted with
TEA-OH.
Action potential recordings. APs were recorded from guinea pig
ventricular cardiomyocytes in the current-clamp mode of the whole
cell patch clamp technique. APs were elicited at 1 Hz by rectangular
current pulses of 4 ms duration at 125% threshold level. The pipette
solution contained 10 mM NaCl, 140 mM KCl, 2 mM EGTA, 1 mM
MgCl2, 0.1 mM Na-GTP, 5 mM Mg-ATP, 10 mM Hepes, pH = 7.2
adjusted with KOH. The cells were bathed in 140 mM NaCl, 4 mM
KCl, 2 mM CaCl2, 2 mM MgCl2, 5 mM HEPES, 5 mM glucose, pH =
7.4 adjusted with NaOH.
Data analysis and curve ﬁtting
Curve ﬁtting was performed with nonlinear least square regression
in Prism 5.01 (GraphPad Software). Normalised hERG activation data
of individual experiments were ﬁt to a Boltzmann function: Inorm =
1 / (1 + exp((V0.5 − V) / K)) where Inorm is the normalised hERG tail
current, V is the membrane potential, V0.5 is the voltage at which half
maximum activation occurred, and K is the slope factor. To assess hERG
channel deactivation, tail currents were ﬁt with a double exponential
function: Itail = Afast ∗ exp(− t / τfast) + Aslow ∗ exp(− t / τslow) + C
(Clampﬁt 10.2), where τfast and τslow are the fast and slow time con-
stants, Afast and Aslow are the respective amplitudes, and C is a con-
stant. Relative amplitudes were determined by dividing by the total
amplitude (e.g. Afast / (Afast + Aslow)). Current–voltage relationships
for hNav1.5 were ﬁt with the function: I = Gmax ∗ (V − Vrev) /
(1 + exp((V0.5 − V)/K)) where I is the current, Gmax is the
maximum conductance (for the remaining parameters see above).
Concentration-response data were ﬁt with a Hill equation: Inorm =
100 / (1 + (IC50/C)^h) where the minimal and maximal values were
constrained to 0% and 100%, respectively. Inorm is the current (%) during
drug exposure in relation to the current during drug-free conditions,
IC50 is the concentration at 50% current inhibition, C is the drug concen-
tration, and h is theHill slope. For all concentration–response curves the
corresponding Hill slopes were between 0.8 and 1.3, thus implicating a
single drug binding site.
Statistical comparisons of data before and after drug application
were performed by paired two-tailed Student's t-tests. One-way
analysis of variance (ANOVA) followed by Tukey's post hoc test was
used when more than two groups had to be compared. A p-value
of b0.05 was considered signiﬁcant. For experiments to assess
the concentration-dependence of channel inhibitions by drugs the
group sizes (=number of experiments (n) performed at different
drug concentrations) were expressed as ranges.
Computer simulation of the human cardiac action potential
A detailed model of a human ventricular cardiomyocyte ((ten
Tusscher et al., 2004), mid-myocardial version) was downloaded
from http://www.cellml.org/models. All simulations were performed
within the CellML environment (Lloyd et al., 2008) with the default
parameters of the model. Action potentials were simulated with a
step size of 0.1 ms and at a rate of 1 Hz. The inhibitory effects of
ibogaine were implemented by adapting the ionic conductances of
the model, gNa for the voltage-gated sodium current, gCaL for the
voltage-gated L-type calcium current, and gKr for hERG potassium
current, according to the observed experimental inhibitions by the
different drug concentrations.
Throughout the manuscript data represent means ± standard
deviation.Results
Drug effects on human ERG potassium channels heterologously expressed
in TSA-201 cells
We have recently reported (Koenig et al., 2012) that ibogaine
concentrations in the low micromolar range inhibit hERG channels
expressed in TSA-201 cells. Here, we characterised ibogaine's
effects on hERG channels in more detail. In addition, we also tested
the effects of its congener 18-Methoxycoronaridine (18-MC). The
structures of the two compounds are compared in Fig. 1a. Fig. 1b
shows typical whole cell currents through hERG channels heterologously
expressed in a TSA-201 cell under drug-free control conditions, and after
steady-state block with 3 μM ibogaine applied from the external side.
These currents were elicited by the pulse protocol depicted on top
from a holding potential of −80 mV. It can be observed that ibogaine
decreased the hERG current amplitude. Endogenous currents in
untransfected TSA-201 cells were small (19 ± 9 pA/pF, Fig. 1c) and did
not contribute to the overall HERG current. To further conﬁrm the
presence of functional hERG channels in our heterologous expression
system, at the end of several experiments, the hERG channel blocker
E-4031 was applied at a concentration of 1 μM. As expected, this drug
completely inhibited the hERG tail currents in TSA-201 cells (data not
shown). Fig. 1d shows a summary of the current–voltage relationships
from seven experiments as shown in b. The current amplitudes were
evaluated at the end of the initial depolarising voltage steps (circles)
and at the peaks of the subsequent tail current (squares), under control
conditions (empty symbols) and under 3 μM ibogaine (ﬁlled symbols).
In the presence of ibogaine, the voltage atwhich halfmaximumactivation
was reached (V0.5) was shifted to more hyperpolarised potentials from
−9.4 ± 3.8 mV in the absence to −18.6 ± 4.5 mV in the presence of
the drug (n = 7; analysis of tail current peaks; p b 0.0001). The corre-
sponding slope factors (K values) were not signiﬁcantly different
and yielded 7.5 ± 0.5 and 7.8 ± 0.7 mV, respectively (p = 0.6). The
observed negative shift in V0.5 under ibogaine could be reversed by
wash out of the drug. V0.5 and K two minutes after beginning of wash
out amounted to−10.1 ± 5.3 and 7.4 ± 0.5 mV, respectively (n = 4).
Finally, the tail currents elicited by the 6 s voltage step to−50 mV
(see Fig. 1b) were further analysed (seven experiments). The decay of
these currents represents the kinetics of hERG channel deactivation
(Chen et al., 1999; Perry et al., 2010). Double exponential ﬁts
to the tail currents revealed the following decay time constants
(τ-values): τfast = 330 ± 70 ms (relative amplitude, 0.46) and
τslow = 2050 ± 380 ms (0.54) in the absence, and τfast = 550 ±
250 ms (0.44) and τslow = 2990 ± 1320 ms (0.56) in the presence
of the drug. A paired Student's t-test between control and 3 μM
ibogaine for τfast and τslow yielded p b 0.05 and p = 0.05, respectively.
The relative amplitudes given in brackets were unchanged. Thus, under
3 μM ibogaine, hERG channel deactivation was considerably slowed.
This effect was fully reversible after washout.
The concentration-dependence of hERG channel inhibition by
ibogaine and 18-MC was determined as in our previous study
(Koenig et al., 2012) by the pulse protocol shown in Fig. 2a, applied
at a frequency of 1 Hz. An activating voltage step was followed by
a 300 ms pulse to −120 mV to elicit a large tail current. In
untransfected cells no tail currents were observed at this potential.
The peaks of the hERG tail currents were measured and plotted over
time in Fig. 2b, which shows part of a typical experiment of drug
application and wash out. We found that 1 and 10 μM ibogaine (ﬁlled
bars) reversibly inhibit hERG currents in a concentration-dependent
manner. Similarly, 10 μM of the ibogaine congener 18-MC (empty
bar), reversibly inhibited hERG currents but to a somewhat lesser
extent when compared to the same concentration of ibogaine
(Fig. 2b). A summary of the concentration-dependencies of current
inhibition by ibogaine and 18-MC from a series of such experiments
(n = 4–17 and 4–13 for ibogaine and 18-MC, respectively) is
Istep control
Istep 3µM ibogaine
Itail control
Itail 3µM ibogaine
control
untransfected
cb
d
2 s
10
0 
pA
/p
F
2 s
10
0 
pA
/p
F
3 µM ibogaine
-80 mV
+60 mV
-50 mV6 s
4 s
-60 -40 -20 0 20 40 60 80
0.0
0.2
0.4
0.6
0.8
1.0
voltage (mV)
n
o
rm
 h
ER
G
 c
ur
re
nt
a ibogaine 18-Methoxycoronaridine (18-MC)
Fig. 1. hERG potassium channel blockade by ibogaine. (a) Chemical structure comparison between ibogaine and 18-MC. (b) Typical whole cell currents through hERG potassium
channels heterologously expressed in a TSA-201 cell. Currents elicited by the pulse protocol on top under control conditions, and after steady-state level was reached during
superfusion with bath solution containing 3 μM ibogaine are displayed. In addition, typical endogenous currents of an untransfected TSA cell, elicited by the same pulse protocol,
are shown (c). (d) Summary of the current–voltage relationships under control conditions (empty symbols) and under steady-state block with 3 μM ibogaine (ﬁlled symbols).
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pulse to −50 mV, and plotted against the applied voltage. The solid lines connect the single data points. Values represent means ± standard deviation.
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measured after a new steady-state level was reached during an
external solution change, were plotted against drug concentration.
Note that the ibogaine data were taken from Fig. 1b of our earlier study
(Koenig et al., 2012; licence number, 2995391353547). Fits of the
data points with a Hill equation revealed IC50 values of 3.9 ± 0.3 μM
(Koenig et al., 2012) and 14.9 ± 0.8 μM (present study) for ibogaine
and 18-MC, respectively. The corresponding Hill slopes were 0.8 and
0.9, and thus close to one, consistent with the presence of a single drug
binding site.
Numerous drugs are known to increase their inhibition of hERG
channels if the cell membrane is depolarised frequently, a phenomenon
which is referred to as frequency-dependent block. To test if ibogaine
inhibits hERG channels in a frequency-dependent manner, we ﬁrst
applied 3 μM ibogaine for 2 min to allow for a basal block without
pulsing. This was followed by repetitive pulsing at low (0.1 Hz)
and high (1 Hz) frequency for 60 s. The hERG tail current amplitudes
normalised to the drug-free control condition (data point at 60 s)
are shown in Fig. 2d. Upon repetitive pulsing a minor additional
block developed at both frequencies. Thus, 60 s of 0.1 Hz and 1 Hz
pulsing decreased the currents by an additional 15 ± 1% (n = 6)
and 10 ± 7% (n = 7) compared to basal block levels, respectively.
Consequently, 3 μM ibogaine does not generate considerable
frequency-dependent hERG channel block.Drug effects on human Nav1.5 sodium channels heterologously expressed
in TSA-201 cells
Besides hERG potassium channels, hNav1.5 sodium channels are
also of major importance in the human heart (Terrenoire et al.,
2007). Since brain sodium channels were previously identiﬁed as
one possible target site for ibogaine's actions (Glick et al., 2000),
here we tested if ibogaine and its congener 18-MC also affect the
currents through cardiac hNav1.5 channels.
In Fig. 3a, typical whole cell currents through human Nav1.5 sodium
channels heterologously expressed in a TSA-201 cell are shown under
control conditions, after steady-state block with 100 μM externally
applied ibogaine, and after wash out. The currents were elicited by
the pulse protocol given in the inset of Fig. 3b. From a series of such
experiments the inward current peaks were plotted against the applied
voltage to obtain the current–voltage relationships (Fig. 3b). As can be
observed in this ﬁgure and in the original traces of Fig. 3a, 100 μM
ibogaine considerably reduced the sodium currents through hNav1.5
channels. Moreover, in the presence of the drug, the current–voltage
relation was slightly shifted to more hyperpolarized potentials. Thus,
the voltage of half maximal activation (V0.5) was −42 ± 5 mV in the
absence and −46 ± 5 mV in the presence of 100 μM ibogaine
(p b 0.01, n = 7). The corresponding slope factors (K values) were
6.2 ± 0.8 and 5.5 ± 0.5 mV (p b 0.05), respectively. V0.5 after two
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amounted to 6.7 ± 0.7 mV (n = 7).
The concentration-dependence of hNav1.5 channel inhibition by
ibogaine and 18-MC was determined by repetitive (0.5 Hz) 25 ms
voltage steps to −10 mV from a holding potential of −120 mV
(Fig. 3c). The elicited peak inward sodium current amplitudes were
allowed to equilibrate until a stable condition had developed.
Thereafter, different drug concentrations were washed in, and
steady-state block level was determined. A complete wash out of
the drug after each application served to conﬁrm the control level
before drug application. A summary of the concentration-dependent
current inhibitions is shown in Fig. 3c. Fits of the data points with a
Hill equation revealed IC50 values of 142 ± 11 μM (n = 5–10) and
464 ± 34 μM (n = 6–12) for ibogaine and 18-MC, respectively. The
corresponding Hill slope was 1.1 for ibogaine, and it was constrained
to 1 in case of 18-MC to give a reasonable estimation of the IC50 value,
as 300 μMwas the highest 18-MC concentration that could be applied
(see Materials and methods).
Next we tested if hNav1.5 channels are inhibited by ibogaine in
a frequency-dependent manner. Therefore, either under control
conditions or 2 min after start of superfusion with 10 or 100 μM
ibogaine, repetitive high frequency pulsing (pulse protocol from
Fig. 3c applied at 5 Hz) was started. The current peaks normalised
to the respective control (drug-free condition) were plotted against
time in Fig. 3d. As expected from the drug's concentration-
dependence (Fig. 3c), 10 μM ibogaine generated only a minor basal
block (see ﬁrst data point). A considerable frequency-dependent
decline in the current amplitude during repetitive 5 Hz pulsing
could not be observed. Thus, the steady-state current level reached
after 2 s of pulsing amounted to 96 ± 6% (n = 7) of the control
(Fig. 3d). 100 μM ibogaine, on the other hand, inhibited the basalcurrent to about 65% of the control, and generated a little further
current reduction during repetitive pulsing (steady-state current
level after 2 s, 52 ± 20% (n = 8); Fig. 3d). The corresponding
steady-state current levels reached during repetitive 0.5 Hz pulsing
were 93 ± 4% (n = 10) under 10 μM, and 65 ± 7% (n = 9) under
100 μM ibogaine.
Taken together, compared to hERG channel inhibition, signiﬁcantly
higher concentrations of ibogaine and 18-MC are needed to block
hNav1.5 sodium channels. This ﬁnding is in line with previous
observations suggesting that many drugs have a higher afﬁnity to
hERG than to other cardiac ion channels (Perry et al., 2010).
Ibogaine's effects on the action potential in adult ventricular guinea pig
cardiomyocytes
After having characterised ibogaine's hERG channel inhibition and
the drug's lower afﬁnity inhibitory action on cardiac voltage-gated
sodium channels, we next studied the effects of ibogaine on the
cardiac action potential (AP). For this purpose we used cardiomyocytes
isolated from adult guinea pig ventricles, which are considered an
appropriate model system to study drug effects on the human cardiac
AP (e.g. (Davie et al., 2004; Yao et al., 2008)).
APs were recorded from single ventricular cardiomyocytes in the
current-clamp mode. To validate our system, we ﬁrst used the hERG
channel blocker E-4031. As shown in Fig. 4a, externally applied
E-4031 considerably prolonged the AP, as expected from a hERG
channel blocker. Secondly, the L-type calcium channel blocker
isradipine, which should shorten the AP, indeed reduced AP duration
(Fig. 4b). After having performed these control experiments we tested
the effects of ibogaine. Typical original traces under drug-free control
conditions, and after steady-state level was reached following external
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Fig. 3. hNav1.5 sodium channel blockade by ibogaine. (a) Typical currents through hNav1.5 channels expressed in a TSA-201 cell under control conditions, after steady-state level
was reached during superfusion with high sodium bath solution containing 100 μM ibogaine, and after wash out. The currents were elicited by the pulse protocol given in the inset
of b. (b) Summary of the current–voltage relationships under control conditions and under inhibition with 100 μM ibogaine. The current peaks were plotted against the voltage. The
solid lines represent best non-linear ﬁts to the data points (function described in Materials and methods). (c) hNav1.5 current inhibition by various concentrations of ibogaine and
18-MC. The pulse protocol to elicit the currents (inset) during the sequence of drug application and wash out was applied at a frequency of 0.5 Hz. The lines represent sigmoidal ﬁts
to the data points with a Hill equation; for 18-MC the slope was constrained to 1. (d) hNav1.5 current reduction during repetitive high frequency (5 Hz) pulsing. The pulse protocol
under experimental conditions (10 μM and 100 μM ibogaine) was always started 2 min after beginning of superfusion with bath solution containing the drug.
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Fig. 4c. It can be observed that 1 μM ibogaine did not considerably
affect AP duration. This result was unexpected considering that this
ibogaine concentration considerably blocks hERG channels (see Fig. 2).
Furthermore, under 10 μM ibogaine AP duration was even signiﬁcantly
reduced, an effect that was dramatic under 100 μM drug concentration.
Analyses of a series of such experiments (n = 5–21) on guinea pig
cardiomyocytes are depicted in Figs. 4d and e. Here AP durations at 90%
repolarisation (APD90, d), and the area under the AP (e) were plotted
against ibogaine concentration. Both graphs suggest that low ibogaine
concentrations (0.1–3 μM) do not alter AP duration. Interestingly,
however, at a concentration of 1 μM, the drug occasionally generated
recognisable AP prolongation. This effect was observed only at this
particular ibogaine concentration, and only in two out of six tested
cardiomyocytes, where it was reversible and appeared repeatedly after
washout. Note that due to these two “outliers” the standard deviation
for this data point (at 1 μM drug concentration) is abnormally large.
Finally, higher ibogaine concentrations (≥10 μM) caused a signiﬁcant
shortening of the AP, as reﬂected by a decrease in the APD90 and AP
area values (Figs. 4d and e). In an effort to better understand the lack
of effects of ibogaine on the guinea pig AP despite showing potency
for hERG, we studied the effects of the drug on the L-type calcium
channel in more details. Thus, it seemed possible that a prominent
inhibition of L-type calcium channels in guinea pig cardiomyocytes
could counteract ibogaine's AP-prolonging effect generated by hERG
channel blockade. Investigation of this issue in guinea pig cardiomyocytes
(Fig. 4f) indeed revealed that ibogaine has a comparatively high afﬁnity
for calcium channels in this particular cell system (IC50, 53 ± 4 μM(n = 5–14); Hill slope, 1). Consequently, in guinea pig cardiomyocytes,
10 μM ibogaine inhibits the currents through calcium channels by
approximately 20% (Fig. 4f), which may constitute a compensatory
mechanism to counteract and even exceed the AP-prolonging effect of
ibogaine's hERG channel blockade.
Computer simulation to estimate the net effect of ibogaine's multiple ion
channel inhibitory actions on the human AP
Several reports of QT interval prolongation after ibogaine intake
in humans (Hoelen et al., 2009; Paling et al., 2012; Pleskovic et al.,
2012) suggest that the drug, unlike in guinea pig ventricular
cardiomyocytes, prolongs the AP in human cardiomyocytes. To test
this hypothesis, we used the data already obtained with ibogaine on
hERG and hNav1.5, generated the data for hCav1.2, and used these
results to deﬁne the effects of ibogaine on a computer model of a
human ventricular AP. hCav1.2 expressed in TSA-201 cells was
blocked by ibogaine with an IC50 value of 163 μM (Hill slope, 0.9;
Fig. 4f), a value approximately 3-fold larger than that obtained in
guinea pig cardiomyocytes.
Fig. 5 shows the effects of hERG, hNav1.5, and hCav1.2 current
inhibition on the AP at three different ibogaine concentrations. At
1 μM ibogaine, the simulations revealed that hERG current inhibition
slightly prolongs the duration of the AP, when compared to the
drug-free control condition (Fig. 5a). Calcium channel inhibition, on
the other hand, did not generate any effect on the AP at this low
drug concentration. At 10 μM ibogaine, hERG blockade considerably
prolonged, and calcium channel blockade slightly shortened the
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Fig. 4. Effects of ibogaine on the action potential (AP) in guinea pig ventricular cardiomyocytes. During drug application and wash out experiments, APs were elicited at a frequency
of 1 Hz. Ten consecutive traces were averaged for each depicted AP. (a) AP under control conditions, and at various time points after beginning of superfusion with bath solution
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application. (b) AP under control conditions, 1 min after beginning of superfusion with bath solution containing 10 μM isradipine, and 3 min after wash out. (c) AP under control
conditions, and each time after steady-state was reached during superfusion with bath solution containing 1, 10 and 100 μM ibogaine. The ibogaine effect on the AP was completely
reversible after wash out (data not shown). (d) Concentration-dependence of the ibogaine effect on AP durations at 90% repolarisation (APD90). (e) Concentration-dependence of
the ibogaine effect on the area under the AP. A signiﬁcant difference existed among the different drug concentrations (p b 0.0001, ANOVA). *** indicates a signiﬁcant difference to
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and wash out is shown in the inset. The lines represent sigmoidal ﬁts to the data points with a Hill equation.
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considered together (Fig. 5b). At both 1 and 10 μM ibogaine,
hNav1.5 current inhibition by the drug did not exert any noticeable
effect on the AP. Therefore the respective traces were omitted.
At the highest ibogaine concentration (100 μM) all ion channel
inhibitions generated signiﬁcant effects on the AP (Fig. 5c). First
hERG blockade prolonged the AP. Secondly calcium channel blockade
shortened the AP duration, and diminished the positive membrane
potential reached during the plateau phase of the AP. Thirdly
hNav1.5 blockade slowed the upstroke and reduced the amplitude
of the AP (inset of Fig. 5c). Finally, when hERG and hCav1.2 channel
inhibition at 100 μM ibogaine were considered together, hardly any
effect on AP duration remained. Thus, at this high drug concentration,
calcium channel inhibition obviously neutralised the effect produced
by hERG channel blockade.
Taken together, the computer simulations revealed that low
micromolar concentrations of ibogaine prolong the human cardiac
AP due to hERG channel inhibition. The higher the ibogaine concentration
becomes (already evident at 10 μM), themore calcium channel inhibition
by the drug counteracts the AP-prolonging effect generated by hERG
channel blockade.Human plasma protein binding of ibogaine
In an effort to deﬁne whether the concentrations used in this
study could translate to reported clinical exposure, we determined
the human plasma protein binding fraction of ibogaine using an
equilibrium dialysis method (Cyprotex Discovery, Macclesﬁeld, UK)
and found it to be approximately 65%.
Discussion
Here we report that low micromolar concentrations of ibogaine, a
drug with promising anti-addictive properties, inhibit cardiac
voltage-gated ion channels. The strongest potency of ibogaine we
found here relates to hERG channels, and the drug concentration
required to inhibit hERG currents by 50% (IC50) was 4 μM (Koenig
et al., 2012; present study). Ibogaine concentrations have been
measured in whole blood samples of humans after single oral doses
of 500–1000 mg (Mash et al., 1998, 2000), doses that are typically
employed to treat drug addicts (10–25 mg/kg of body weight)
(Alper, 2001; Mash et al., 1998, 2000), and in a case of ibogaine
poisoning (Kontrimaviciute et al., 2006). The values obtained were
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the extent of ibogaine's human plasma protein binding of 65% taken
into account, the free plasma concentrations reached after drug
intake in these studies amounted to 1–11 μM. Together this suggests
that therapeutic concentrations of ibogaine directly inhibit hERG
channels in the human heart.
Ibogaine's multiple ion channel inhibitory actions: prolongation or
shortening of the cardiac AP?
hERG channel blockade by drugs is known to delay the
repolarisation phase of the cardiac AP, which usually goes along
with a prolongation in AP duration. Here, although conﬁrming
ibogaine's inhibitory effect on hERG channels (Koenig et al., 2012),
surprisingly, we did not observe the expected AP prolongation in
guinea pig cardiomyocytes by ibogaine in any of the concentrations
(range, 0.1–100 μM) used. On the contrary, higher ibogaine
concentrations (≥10 μM) even shortened AP duration signiﬁcantly. To
reconcile this discrepancy, here we propose that ibogaine's effects on
L-type calcium channels, which normally depolarise the membrane
potential when activated, counteract AP prolongation due to ERG
channel inhibition by the drug. This is supported by the fact that low
micromolar ibogaine concentrations inhibit the currents through
calcium channels in guinea pig cardiomyocytes. Thus at 10 μM ibogaine
(minimum drug concentration required to induce AP shortening),
the currents through calcium channels are already reduced by
approximately 20% (Fig. 4f; IC50, 53 μM). In guinea pig cardiomyocytes
ibogaine seems to display a proﬁle similar to the calcium channel
blocker verapamil. Verapamil inhibits both hERG and calcium channels
at therapeutic concentrations and does not induce a prolongation of
the cardiac AP (e.g. (Redfern et al., 2003)). On the other hand,
when implementing both ibogaine's human ERG and Cav1.2 channel
inhibitions in a computer model of a human cardiac AP, the drugproduced considerable AP prolongation at certain concentrations
(Fig. 5). Here, e.g. at 10 μM, ibogaine's inhibitory effect on hCav1.2
channels (Fig. 4f; IC50, 163 μM) only partly counteracts its hERG
channel blocking effects.
Together these ﬁndings strongly suggest that calcium channel
blockade by ibogaine counteracts the AP-prolonging effect of ERG
channel inhibition by the drug. This effect occurs more prominently
in guinea pig (experimental data) compared with human (computer
simulation) cardiomyocytes, probably due to the 3-fold higher
afﬁnity of ibogaine for guinea pig versus human calcium channels.
As a consequence, only the human, but not the guinea pig cardiac
AP is prolonged by ibogaine in low micromolar concentrations.
Species differences in drug afﬁnities for ion channels, as observed
for the effects of ibogaine on L-type calcium channels in the
present study, have previously been reported (e.g. (Grace and
Camm, 2000)). Because in the present study we did not have the
possibility to measure APs in human ventricular cardiomyocytes but
performed computer simulations instead, however, these interpretations
remain speculative.
It should be noted here that also other factors may have contributed
to the different actions of ibogaine on the AP in guinea pig and human.
First, the drug may have a lower afﬁnity for the guinea pig compared
with the human ERG channel. Secondly, the contribution of ERG
currents to the repolarisation phase of the cardiac AP may be larger
in human compared to guinea pig hearts (O'Hara and Rudy, 2012;
Zicha et al., 2003). Thus, in the latter, a more signiﬁcant part of the
repolarisation may be carried by the slow delayed rectiﬁer potassium
current IKs, which is strongly expressed in guinea pig ventricular
cardiomyocytes (Sanguinetti and Jurkiewicz, 1990). Consequently, ERG
channel blockade by ibogaine would have a stronger AP-prolonging
effect in human than in guinea pig cardiomyocytes. Finally, we can also
not exclude the possibility that ibogaine additionally affects other
cardiac ion channels than ERG and calcium channels,which are expressed
267X. Koenig et al. / Toxicology and Applied Pharmacology 273 (2013) 259–268in guinea pig cardiomyocytes, but were not considered in our human AP
simulations.
Does ibogaine contribute to QT interval prolongation in humans?
Ibogaine is known to affect the cardiovascular system. The drug
slows the heart rate in animals (Binienda et al., 1998; Glick et al.,
2000) and humans (Alper, 2001; Glick et al., 2000; Maciulaitis et al.,
2008). This effect is probably mediated via interaction of ibogaine
with muscarinic acetylcholine receptors (Alper, 2001; Glick and
Maisonneuve, 2000; Glick et al., 2000). Moreover, cardiac arrhythmias
have been related to several cases of sudden death after ibogaine
intake (Alper et al., 2012; Hoelen et al., 2009; Maas and Strubelt, 2006).
However, due to concomitant medications used and comorbidities
(e.g. cardiovascular) present in the patients described in these cases
(Alper et al., 2012; Donnelly, 2011), it is unclear whether indeed ibogaine
has caused these deaths. First direct evidence for ibogaine-induced
arrhythmias was provided by Hoelen et al. (2009). These authors
reported a severe prolonged QT interval of the electrocardiogram,
associated with ventricular tachyarrhythmias, in a 31-year-old woman
after she had taken a single dose of ibogaine. Other cases of
ibogaine-associatedQT interval prolongation and ventricular arrhythmias
were recently published (Paling et al., 2012; Pleskovic et al., 2012).
In the present study, we describe both ibogaine effects on cardiac
ion channels that favour (hERG channel inhibition) and counteract
(calcium channel inhibition) AP prolongation. Because ibogaine's
afﬁnity for human ERG channels is considerably higher (40-fold)
than that for human Cav1.2 channels, we propose that the drug can
prolong AP duration in human ventricular cardiomyocytes, and
thereby has the propensity to prolong the QT interval. It should be
noted here, however, that although most probably insufﬁcient to
fully counteract AP prolongation due to hERG channel inhibition,
calcium channel blockade will in any case diminish the amount of
QT interval prolongation generated by the drug (e.g. at 10 μM
ibogaine, see Fig. 5b). Here, another consideration is noteworthy:
with the exception of the patient recently described in Pleskovic et
al. (2012), the other reported cases of QT interval prolongation after
ibogaine intake in humans (Hoelen et al., 2009; Paling et al., 2012)
were all accompanied by hypokalaemia. Hypokalaemia has been
shown to reduce the cell surface density of hERG channels, and
exacerbates long QT syndrome (Guo et al., 2009). Thus, it cannot un-
equivocally be judged, whether the cases of QT prolongation reported
(Hoelen et al., 2009; Paling et al., 2012) can solely be attributed to
the direct inhibitory effect of ibogaine on hERG channels in these
patients. Moreover, low extracellular potassium may also increase
drug blockade of IKr (Yang and Roden, 1996). If this is also true for
ibogaine, hypokalaemia may enhance the direct QT prolonging
effect of the drug via hERG channel inhibition. Finally, besides QT
prolongation as a possible consequence of hERG inhibition, it should
be noted that the application of a powerful psychoactive drug such
as ibogaine may also lead to cardiac adverse effects related to its
central nervous activity without the need to imply hERG inhibition.
Regardless of the actual mechanism underlying the potential
ibogaine-induced QT prolongation, this condition may likely be
detrimental for humans at high risk such as in the case of drug
addicts.
Is the ibogaine congener 18-Methoxycoronaridine safer than ibogaine?
In this study, besides ibogaine, we also tested its synthetic congener
18-MC, which is believed to be less toxic (Glick et al., 1996, 2000, 2001,
2011). We found that, similar to ibogaine, 18-MC inhibits hERG and
hNav1.5 channels heterologously expressed in TSA-201 cells. For the
inhibition of both these currents, however, higher concentrations of
18-MC were needed when compared to ibogaine. This suggests that the
afﬁnity of 18-MC to cardiac voltage-gated ion channels is lower thanthat of ibogaine. In accord, Glick et al. (2000) reported that 18-MC has a
lower afﬁnity for rat brain sodium channels than ibogaine. In principle,
the lower afﬁnities of 18-MC for cardiac ion channels suggest a reduced
risk for cardiac adverse effects in comparison with ibogaine. However,
18-MC's afﬁnity for hERG channels (IC50, 15 μM) is still close to the
therapeutic concentration range (see above), if similar plasma protein
binding as for ibogaine is assumed. Thus, like ibogaine, 18-MC may have
the propensity to induce QT interval prolongation by hERG channel
inhibition. 3- to 4-fold higher concentrations of 18-MC, however, may
be needed to trigger this effect. Finally, it should be mentioned that a
racemate of 18-MC was used here for testing. This may restrict the
conclusions drawn, because single enantiomers could possess different
ion channel activities.
Limitations of the study
The current inhibition data used for the human AP computer
simulations originated from human ion channels (hERG, hNav1.5,
and hCav1.2) heterologously expressed in TSA-201 cells. Drug
afﬁnities for ion channels in native cells can differ from those
detected in heterologous expression systems. Thus, our simulations
can only provide an estimate of the real situation in native human
cardiomyocytes. This certainly limits our predictions about ibogaine's
effects on the heart's electrophysiology in humans. We are also
aware that, by assessing the cardiac ion channel proﬁle of ibogaine
(and 18-MC), we did not directly test proarrhythmia liability or
vulnerability.
In conclusion, we found that ibogaine inhibits cardiac voltage-
gated ion channels. At therapeutic concentrations, the drug's inhibitory
effect on hERG channels provides a potential explanation for the reported
QT interval prolongation in humans that may lead in some cases to
tachyarrhythmias. Ibogaine derivatives with reduced propensity to
block cardiac ion channels but preserved anti-addictive properties need
to be developed. 18-MC may be regarded as a ﬁrst candidate.
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